In the ovarian cancer trials (e.g., SOLO-1, PRMIA)2,7 PARP inhibitors were employed for at least 2 years or until progression, compared to the 1 year of adjuvant olaparib in OlympiA. The gene discussed is PARP1; the disease is ovarian carcinoma.